Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GPBAR1 (TGR5) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GPBAR1 Membrane Prep / Mutant Protein (including key polymorphisms V88I, M112T). High purity, native conformation preserved. Sequence Verified. | View GPBAR1 Products |
| Gene Delivery | GPBAR1 Lentivirus Particles / Promise-ORF Full-length ORF for stable cell lines (Crucial for GPCR assays). HEK293 Expressed. |
View GPBAR1 Products |
| Benchmark Ab | Anti-GPBAR1 Benchmark Antibody (INT-777 Analog) Recombinant positive control for expression and binding validation. |
View GPBAR1 Products |
| Validator | GPBAR1 siRNA Set For knockdown verification and specificity checks. |
View GPBAR1 Products |
| Related Target A | FXR (NR1H4) Synergistic bile acid receptor for NASH/MASH combination screening. |
View FXR Products |
| Related Target B | GLP1R Downstream incretin target in metabolic syndrome; TGR5 activation induces GLP-1 secretion. |
View GLP1R Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Native Conformation Preservation | Lentivirus-mediated stable expression in HEK293 cells maintains native glycosylation and 7-TM topology. |
| Gs/cAMP Signaling Detection | Full-length GPBAR1 lentivirus enables functional cAMP accumulation assays (HTRF/FlashPlate compatible). |
| Species Cross-reactivity (Preclinical) | Human/Mouse/Rat/Cyno ortholog lentivirus particles available; sequence identity >80% verified. |
| Selectivity vs FXR/PXR/CAR | Specific siRNA and negative control proteins for off-target liability screening included. |
| Biased Agonism Screening | Mutant variants (e.g., Sinecodon modifications) available for pathway-selective validation. |
| Lack of Positive Controls | Recombinant benchmark antibodies for FACS and assay setup. |
Live GPBAR1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ TGR5 Specific Trials
- ➤ Latest Resistance & Polymorphism Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for GPBAR1 (TGR5) therapeutics is intensifying, with major players shifting focus from systemic agonists to intestine-restricted and biased modalities. First-generation pan-agonists (e.g., INT-777) demonstrated efficacy in NASH and Type 2 Diabetes but encountered gallbladder-related safety limitations (pruritus, gallbladder filling). The next wave of R&D is targeting pathway-biased signaling (cAMP vs β-arrestin) to preserve metabolic benefits while minimizing off-target effects. The convergence of TGR5 agonism with GLP-1R co-agonism represents a critical frontier for combination metabolic therapy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Agonists | Intercept, Merck, Novartis, Metacrine | NASH / MASH, Type 2 Diabetes | cAMP functional assay (Lentivirus-stable cells required) |
| Gut-restricted / Intestine-Restricted | Takeda, vTv Therapeutics | Type 2 Diabetes, Metabolic Syndrome | Cell line construction for enterocyte models; receptor selectivity (sequence-verified clones) |
| Dual Agonists (FXR/TGR5) | Enanta, Novartis | Fibrosis / Obesity | Multiplexing capability (high-purity panels) |
| Biased Agonists (β-arr) | Structure-based biotechs | IBD, Fibrosis | Pathway-selective reporter assay (mutant receptors for validation) |